Biotech & Life Sciences
Intellia Stock Rises on FDA Clearance for CRISPR Therapy
NTLA performance by TradingView Intellia Therapeutics (NASDAQ: NTLA) saw shares rise after the FDA lifted a clinical hold on one of its Phase 3 trials for nexiguran ziclumeran (nex-z), a CRISPR-based therapy for transthyretin amyloidosis (ATTR). What Happened Last October, U.S. regulators paused two trials after a participant died from severe liver toxicity. The cleared…
From Biotech CEO to Prison: Inside the CytoDyn Fraud Case
CYDY performance by TradingView A former biotech executive has been sentenced to prison after being found guilty of misleading investors and selling his own shares at inflated prices. Nader Pourhassan, 62, of Lake Oswego, Oregon, was sentenced to 30 months in federal prison for securities fraud related to false claims about a drug his company…
New LEQEMBI Shot Lets Alzheimer’s Patients Skip Clinic Visits
BIIB performance by TradingView Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) announced that the FDA has accepted a review for their new subcutaneous (under-the-skin) version of LEQEMBI, called LEQEMBI IQLIK, for people with early Alzheimer’s disease. The FDA has given it Priority Review, with a decision expected by May 24, 2026. If approved, this version…
Sanofi’s Amlitelimab Clears Regulatory Bar, Raises New Investor Doubts
SNY performance by TradingView Sanofi (NASDAQ: SNY, Euronext Paris: SAN)’s amlitelimab still looks like a viable U.S. approval candidate, but it is no longer the clear successor to Dupixent that investors once hoped for. The latest data keeps the program alive from a regulatory standpoint, yet introduces enough uncertainty that the stock is unlikely to…
Experienced Biotech Executives Launch New Rare Disease Startup
Another rare disease startup is entering the market, this time backed by a group of executives who have been here before. Mendra, a new biotech led by former BioMarin and Escient Pharmaceuticals executives, has raised $82 million in a Series A round led by OrbiMed, 8VC, and 5AM Ventures. The company says the capital will…
China Becomes New Hunting Ground for Obesity Drugs
Corxel’s latest funding round lands at a time when U.S. and European drug developers are increasingly sourcing new medicines from China. Over the past few years, both large pharmaceutical companies and venture-backed biotech firms have shown a willingness to license compounds discovered in Chinese labs and move them quickly into Western clinical programs. That strategy…
New Study Shows Brain Processes Language Like AI Models
For years, neuroscientists have debated how people actually make sense of spoken language. Is it driven by strict rules, or does meaning slowly come together as we hear more words? A new study suggests it is the latter. And interestingly, the process looks a lot like how modern AI language models handle text. What the…
JNJ Earnings Hit Growth, But Patent Losses Threaten Future Sales
Johnson & Johnson (NYSE: JNJ) shares fell about 1 percent in early Wednesday trading as investors digested the company’s latest earnings report. Management highlighted confidence in the business, with CEO Joaquin Duato calling the company’s lineup the strongest it has ever had. The market response suggested lingering doubts. Concerns remain around patent losses, litigation exposure,…
Corvus’ Experimental Drug Delivers Strong Results in Hard-to-Treat AD
Corvus Pharmaceuticals (NASDAQ: CRVS) announced encouraging results from cohort 4 of its Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. The data show good safety and efficacy, similar to earlier cohorts, and suggest longer treatment may improve responses. Cohort 4 Results Cohort 4 included 12 patients on soquelitinib and 12 on placebo.…
The Hidden Investing Risk No One Talks About: Cognitive Decline
Investors spend a lot of time debating valuations, interest rates, and where the next recession might come from. Very little time is spent on something that is arguably just as important over the long run: whether we remain capable of making good financial decisions as we age. That is not a comfortable topic. It also…
